Description

Bendamustine 100mg Injection is an anti-cancer medication used to treat certain types of blood cancer, such as chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (NHL).                                                                                                                                                                            Bendamustine 100mg Injection has several unique features:

1. Mechanism of Action: Bendamustine is a bifunctional alkylating agent that contains a mechlorethamine group and a benzimidazole ring. This unique structure allows it to damage the DNA and RNA of cancer cells, inhibiting their growth and division.
2. Approved Indications: Bendamustine is approved for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin’s lymphoma (NHL), two types of blood cancers. This targeted use is a unique feature compared to more broadly used chemotherapies.
3. Dosing and Administration: Bendamustine is administered as an intravenous infusion, typically over 30-60 minutes, on days 1 and 2 of a 21-28 day treatment cycle. This intermittent dosing schedule is a unique aspect of the medication.
4. Potential Side Effects: Bendamustine can cause serious side effects like myelosuppression, infections, tumor lysis syndrome, and skin reactions. Monitoring and management of these potential toxicities is an important unique consideration with this medication.
5. Pharmacokinetics: Bendamustine is rapidly cleared from the plasma, with 93% of the dose cleared within 7 hours. This fast clearance is a unique pharmacokinetic property compared to other chemotherapies.

In summary, the unique features of Bendamustine 100mg Injection include its novel mechanism of action, targeted indications, intermittent dosing schedule, potential for serious side effects, and rapid plasma clearance, all of which require careful consideration by healthcare providers when prescribing this medication.

Key Ingredients

• Bendamustine hydrochloride (active ingredient)
• Mannitol (excipient)

Key Benefits

1. Treats chronic lymphocytic leukemia (CLL) and relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL)
2. Prevents cancer cell growth by interfering with DNA
3. Administered intravenously on days 1 and 2 of a 21-28 day cycle, up to 6-8 cycles